Richard Jefferys of Treatment Action Group discusses the pipeline for new modalities being explored for treatment, PrEP, vaccine, and cure.
This researcher has some ideas about what we need to do to address the problem.
Two researchers discuss their analysis of Philadelphia FIGHT’s HIV pre-exposure prophylaxis (PrEP) program for cisgender women.
Dr. Melanie Thompson discusses what’s happening in the state around coronavirus, and what it means for people living with HIV.
Retire? No, Thanks! This Doc Instead Moved to West Virginia to Fight HIV, Hepatitis C, and the Opioid Crisis
In a poor and conservative state, Judith Feinberg, M.D., aims to expand harm reduction—and bring treatment to active drug users.
Oral Arguments in Antitrust Case Against HIV Drug Companies Began Last Week. Plaintiff Peter Staley Explains the Case
The case could change the way pharma companies make agreements to keep generic versions of single-tablet pills at bay.
Ending the HIV Epidemic Is a Team Effort. The New York City and State Health Departments Discuss Their Combined Work
Johanne Morne, M.S., and Oni Blackstock, M.D., sat down with TheBody to discuss their successes and their work to close the disparities gap.
Even after a series of reforms in 2015, advocates say U.S. policy still discriminates and furthers HIV stigma. Anthony Santella, Dr.P.H., M.P.H., has a better idea.
Primary care providers need more education when it comes to PrEP, not only for them, but also for patients, who often think they need to see a specialist just to take this preventative medicine.
Does Descovy Really Work Better Than Truvada for PrEP? One Researcher Raises Questions About the DISCOVER Trial Results
Newly presented data from IAS 2019 spark discussion about study populations, study endpoints, and potential weight gain.